Detalhe da pesquisa
1.
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Eur J Cancer
; 196: 113455, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38029480